P-211 - CLINICAL PHARMACOLOGY CHARACTERIZATION OF AMG 119, A CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY TARGETING DELTA-LIKE LIGAND 3 (DLL3), IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (R/R SCLC).
D. Zhou1, L. Byers2, B. Sable3, M. Smit3, N. Hashemi Sadraei3, S. Dutta3, V. Upreti1; 1Amgen Inc., South San Francisco, CA, USA, 2MD Anderson Cancer Center, Houston, TX, USA, 3Amgen Inc., Thousand Oaks, CA, USA.
.jpg "Di Zhou, PhD photo")
.png)